Skip to content

Undiagnosed infections and poor retention in care mean that few US patients fully benefit from HIV treatment

Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial

ART and TB prevention

Virulence of HIV has increased since first reports of AIDS

Social vulnerability associated with lack of satisfaction with health care; doctors need to provide more support

Model shows excellent prognosis for UK gay men with HIV

Ritonavir dose of 50 mg could be sufficient to boost some protease inhibitors, trials needed

Product information for raltegravir updated to warn of Stevens Johnson syndrome and hypersensitivity reaction

Drug combinations pairing AZT and efavirenz have highest resistance risk